Evading HSR Rule 801.90: A $12 Million Intentional Oversight?

The recent $12 million settlement by the Federal Trade Commission (FTC) with Edwards Lifesciences and Genesis MedTech serves as a stark reminder of the critical importance of adhering to HSR Rule 801.90, particularly concerning the intent behind transaction structuring. This significant enforcement action underscores that simply staying below reporting thresholds numerically is insufficient if the underlying purpose is to circumvent regulatory scrutiny.

The Anatomy of an Avoidance Scheme

At the heart of this landmark case lies the 2024 acquisition of JC Medical, initially by Edwards Lifesciences. Edwards purchased JC Medical for $115 million, a figure seemingly below the then-applicable Hart-Scott-Rodino (HSR) reporting threshold. However, this initial transaction was quickly followed by a $25 million investment by Edwards into Genesis MedTech, the parent company of JC Medical. Was this merely coincidental, or a deliberate strategy?

Regulators alleged the two transactions were, in effect, components of a single, integrated deal. When aggregated, the total value of these related transactions — $115 million plus $25 million — surpassed the HSR filing threshold, triggering mandatory notification requirements that were allegedly ignored. Internal communications provided critical evidence, with one particularly damning document reportedly stating the structure was “below the threshold! Intentional.” Such a statement starkly illustrates the perceived intent behind the deal’s design.

This situation presents a crucial question for corporate strategists and legal counsel: does the immediate financial benefit of avoiding a filing outweigh the potential long-term costs of regulatory non-compliance? The $12 million settlement suggests a clear answer, highlighting the FTC’s resolve to challenge what it deems as strategic evasion rather than legitimate structuring. Rule 801.90, often referred to as the “anti-evasion rule,” specifically empowers the FTC and Department of Justice to disregard transaction structures primarily designed to sidestep HSR filing obligations. Its existence signifies that regulators are not merely looking at the letter of the law, but its spirit and purpose.

How Regulators Uncovered the Evasion

The alleged violation in the Edwards-Genesis MedTech case was not immediately apparent, as the original acquisition itself was never reported to the FTC. Instead, the details emerged during a separate and subsequent investigation into Edwards’ attempt to acquire JenaValve, which was JC Medical’s main competitor in the U.S. market. It was during this broader merger investigation that the FTC gained access to internal documents and testimony related to the earlier JC Medical transactions.

The lesson here is profound: a company’s past actions, particularly those indicating a pattern of intent to avoid regulatory oversight, can resurface with significant consequences during unrelated inquiries.

Emails and executive testimony unearthed during the JenaValve probe reportedly revealed the intentional structuring of the JC Medical acquisition and the subsequent investment. This discovery enabled the FTC to apply HSR Rule 801.90, arguing that the separate transactions were orchestrated to circumvent the HSR Act’s notification requirements. The rule allows regulators to look past the superficial structure of a deal to its economic reality and underlying purpose. For companies operating in complex M&A environments, this represents a significant shift from a purely formalistic interpretation of compliance.

What does this mean for future enforcement actions? It suggests a proactive and persistent regulatory environment where past compliance records can influence current and future investigations. Companies must therefore consider the long-term implications of their transaction strategies, recognizing that regulatory scrutiny can extend beyond the immediate deal to encompass a broader historical context.

Navigating Antitrust Compliance: Key Lessons from the Case

The $12 million settlement offers several practical lessons for companies and their antitrust counsel, emphasizing vigilance and transparency in M&A activities. Adherence to HSR Rule 801.90 is not just a legal formality but a testament to a company’s commitment to fair market practices. Ignoring these tenets can lead to severe penalties, reputational damage, and prolonged legal battles.

Key takeaways include:

• Document Legitimate Business Reasons: Clearly articulate and document the genuine business rationale behind any transaction structure. Why was a deal split, or why were certain payments structured in a particular way? Transparency here is paramount.
• Aggregate Related Payments for HSR Thresholds: Always consider whether seemingly separate transactions are, in economic reality, parts of a larger, integrated deal. The FTC will aggregate related payments when assessing HSR thresholds, especially if there’s evidence of intentional segmentation.
• Exercise Caution in Internal Communications: Internal emails and discussions can become powerful evidence of intent. Language suggesting a deliberate strategy to avoid filing requirements can be highly detrimental during investigations.
• Recognize Related Acquisitions May Attract Broader Scrutiny: Investigations into one merger or acquisition can easily expand to uncover previously undisclosed or unfiled transactions, particularly if they involve competitors or related entities.
• Seek Legal Review for Suspicious Structures: Whenever a transaction appears to be specifically designed to avoid HSR filing requirements, it is imperative to seek robust legal review. Proactive compliance advice can prevent costly enforcement actions.

These lessons highlight that the FTC’s enforcement strategy is increasingly focused on the intent behind transaction structures, making a robust and ethical approach to M&A compliance more critical than ever.

HSR Rule 801.90: What Happens Next?

The Edwards Lifesciences settlement signals a clear and uncompromising stance from the FTC: attempts to bypass pre-merger notification requirements, especially through intentional structuring, will not be tolerated. This enforcement action serves as a potent deterrent, reminding all market participants that regulatory bodies possess sophisticated tools and a strong mandate to uphold the integrity of the HSR Act.

For financial institutions and corporations engaged in active M&A, this incident should prompt an immediate review of internal compliance protocols and communication strategies. Are your teams fully aware of the implications of HSR Rule 801.90? The long-term reputational damage and the hefty financial penalties associated with non-compliance far outweigh any perceived short-term advantages of avoiding a filing. Furthermore, the FTC’s ability to uncover past evasions through unrelated investigations demonstrates a persistent and expanding reach. Companies must cultivate a culture of compliance where transparency is valued and legal guidance is sought proactively, not merely reactively.

HSR Compliance and Transaction Structuring – Disclaimer

This article provides general information regarding HSR Rule 801.90 and related antitrust compliance matters and should not be construed as legal or financial advice. The specifics of any transaction and its regulatory obligations depend on individual circumstances. Readers should consult with qualified legal counsel and financial advisors for advice tailored to their particular situation before making any business decisions related to mergers, acquisitions, or investment structuring.